Davis, California November 22, 2016 – Evolve BioSystems, Inc., a mid-stage microbiome company developing novel solutions for gut dysbiosis, is pleased to announce that CEO Dr. David Kyle will be presenting at the European Microbiome Congress on December 1st in London.
The conference will bring together leaders across various disciplines to showcase new technological advances and translational case studies to highlight potential applications and challenges in microbiome science. Dr. Kyle will be presenting Evolve’s microbiome-based solutions for dysbiosis in the infant gut, resulting from pre-term birth, Caesarian-section deliveries, and exclusive use of infant formula.
For more details on the European Microbiome Congress, visit: http://microbiomecongress.com/
To learn more about Evolve BioSystems, visit: www.evolvebiosystems.com
Tracy Shafizadeh, PhD
Director, Scientific Communications
About Evolve BioSystems
Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering. In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.